-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8

Benzinga·03/04/2025 15:45:54
Listen to the news
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8.5 to $8.